MTL-CEBPA  (Synonyms: CEBPA-51)

MTL-CEPBA is a small activating RNA targeting for upregulation of C/EBPα. MTL-CEPBA has anti-inflammatory and anti-cancer activity^[1].

MTL-CEBPA does not significantly change total human CD45⁺ cells, and T lymphocytes (hCD4⁺ and hCD8⁺ T cell subsets) in PB. However, MTL-CEBPA treatment increases CD16⁺ granulocytes and CD14⁺ monocytes in peripheral blood (PB)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MTL-CEBPA (iv; 3 mg/kg; on days 1, 3, and 5) demonstrates the specific activation of its target C/EBPα mRNA and its downstream gene p21 in naive hu-NSG mice^[1].
MTL-CEBPA restores LPS-induced (12.5 μg; ip; single dose) reduction of C/EBPα and downregulates several genes associated with immune and inflammatory response in an LPS-stimulated humanized NSG model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2862057-05-2

Solid

White to off-white

[MTL-CEBPA]

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Jiehua Zhou, et al. Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice. Mol Ther. 2019 May 8;27(5):999-1016.  [Content Brief]

  [2]. Reebye V, Huang KW, Lin V, et al. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. Oncogene. 2018;37(24):3216-3228.  [Content Brief]

  [3]. Combination therapies comprising C/EBPα-targeted short-activating RNA (saRNA). WO2022229644A1